Healthcare & Medical

SSAI Annual Congress and Swiss Autoimmune Liver Disease Meeting 2026

The SSAI Annual Congress and Swiss Autoimmune Liver Disease Meeting brings together professionals in immunology and related fields to discuss advances and research. The 2026 edition will be held in Lugano, Switzerland over two days at the end of August.

Visit the official site Sponsorship open

76Speakers

29Sponsors

29Exhibitors

113On the bill · sessions

59Companies · in total

§I

Speakers

Programmed at SSAI, in alphabetical order.

Alexander Eggel

Bern

Ana Alcaraz-Serna

Lausanne

Andreas Cerny

Lugano

Andreas Kremer

Zürich

Anne Dudeck

Magdeburg DE

Anne Hosmalin

Paris FR

Antonio Galante

Lugano

Bingjie Zhao

Davos Wolfgang

Camillo Ribi

Lausanne

Christina Weber

Zürich

Christine Bernsmeier

Basel

Christoph Hess

Basel

Claudia Mauri

London GB

Claudia Rizzi

Locarno

Daphne Mccarthy

Basel

Davide Robbiani

Bellinzona

David Semela

St. Gallen

Eleonora de Martin

Villejuif FR

Elisa Sorrenti

Bellinzona

Elnaz Arjmand

Bern

Federica Sallusto

Bellinzona

Giandomenica Iezzi

Bellinzona

§II

Agenda

Selected from 113 sessions on the bill.

09:45–09:55
Welcome to the Joint Meeting of SSAI and SASL – AILD
Plenary
09:45 – 10:00
Welcome to Lugano
Plenary
10:00–10:25
Antibody-selective treatment in autoimmunity
Plenary 1: B Cells in Autoimmunity
10:00 – 11:00
Plenary 1: B Cells in Autoimmunity
Plenary
10:30–10:55
B cells across cancer and autoimmunity
Plenary 1: B Cells in Autoimmunity
11:30–11:55
Checkpoint Inhibitor–Induced Hepatotoxicity: Diagnosis and Management
Plenary 2: T Cells in Tolerance and Immunity
11:30 – 12:30
Plenary 2: T Cells in Tolerance and Immunity
Plenary
12:00–12:25
Peripheral immune tolerance mechanisms
Plenary 2: T Cells in Tolerance and Immunity
12:45–12:55
Guided Poster Tour: Targeted discovery of natural NY-ESO-1-specific T-cell receptors from long-term cancer survivors for efficient and safe TCR-T cell therapy
TCR-T cell therapies targeting NY-ESO-1, typically using avidity-enhanced TCRs, show clinical efficacy but are associated with severe toxicities, potentially driven by excessive TC…
Guided Poster Tour

Intermission

Part the Second · For the Buyer

What does it mean when 59 companies show up — and 29 bet on three roles at once?

59 companies. 29 are betting more than once.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page — cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room

29All threespeak · spons · exh

0Sponsoringsponsor only

0Exhibitingexhibitor only

30Companies Speakingspeaker only

The Triple-Threat

ADR-AC GmbH·ALK-Abelló AG·Allergopharma·Association "Research for Life"·AstraZeneca·Beckman Coulter Life Sciences·Bencard AG·Biotest (Schweiz) AG·Careformance GmbH·CSL Behring AG·Euroimmun Schweiz AG·Gilead Sciences Switzerland Sàrl·GlaxoSmithKline AG·iQone Healthcare Switzerland (a Celltrion Company)·KalVista Pharmaceuticals Switzerland GmbH·MediService AG·Moderna Switzerland GmbH·Novartis Pharma Schweiz AG·Octapharma AG·Otsuka Pharmaceutical (Switzerland) GmbH·RUWAG Handels AG·Sanofi-Regeneron

Speakers by seniority

Other roles76100%

Of 76 on the bill · classified by free-text title

Most-represented companies

Sponsors by tier

unspecified29

100% of 29

SSAI Annual Congress and Swiss Autoimmune Liver Disease Meeting 2026

Welcome to the Joint Meeting of SSAI and SASL – AILD

Welcome to Lugano

Antibody-selective treatment in autoimmunity

Plenary 1: B Cells in Autoimmunity

B cells across cancer and autoimmunity

Checkpoint Inhibitor–Induced Hepatotoxicity: Diagnosis and Management

Plenary 2: T Cells in Tolerance and Immunity

Peripheral immune tolerance mechanisms

Guided Poster Tour: Targeted discovery of natural NY-ESO-1-specific T-cell receptors from long-term cancer survivors for efficient and safe TCR-T cell therapy

59 companies. 29 are betting more than once.